A potentially alarming set of data was identified by researchers from the University Medical Center Utrecht report that about 17% of juvenile idiopathic arthritis (JIA) patients treated with biologic agents develop anti-drug antibodies (ADAbs) associated with adverse events.
Published in Rheumatology, the study titled “Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis” reveals that up to 50% of juvenile patients do not respond to initial biologic agent treatment. There is growing evidence that a large number of juveniles experience the treatment loss of effectiveness over time, or juveniles may experience adverse events that cause them to cease taking the therapy immediately. The biologic agents studied included Humira, Orencia, Remicade, Enbrel and others. Follow the link to learn more.